2024年1月24日 · We report that CCR7 + DCs are the dominant DC population that migrate to the dLN, but a subset remains tumour-resident despite CCR7 expression. These tumour-retained CCR7 + DCs are...

2021年7月23日 · CCR7 ligation in DCs induces complicated intracellular signaling pathways involving PI3K/AKT, MAPK/NF-κB, HIF-1α, and IRFs, which feedback to regulate the migratory ability and inflammatory...

成熟和半成熟DC的 CC趋化因子受体7 （CCR7）表达升高，并向表达CCR7配体CC趋化因子配体21（CCL21）的末端淋巴管迁移。 CCR7与CCL21的相互作用使DC进入淋巴管系统，并最终通过淋巴流向引流淋巴结的囊下窦（SCS）被动转运。 在SCS内，CCL21被非典型趋化因子受体4（ACKR4）清除，该受体由SCS上限的淋巴内皮细胞特异性表达。 这会产生一个指向T细胞区域的CCL21梯度，从而允许淋巴来源的DC有效而定向地迁移到该区域。 DC与免疫. DC是先天 …

2024年2月2日 · 2022年11月， Novartis 团队首次在《Blood》杂志公布了JBH-492 的相关研究数据，表明其有可能成为治疗 CCR7 表达淋巴恶性肿瘤的一种前景广阔的ADC候选药物。针对CCR7的研究仍处于早期阶段，需要更多的临床数据来验证其疗效和安全性。

CCR7 is expressed by B cells, mature dendritic cells (DCs) and by several T-cell sub-populations including naive, regulatory and central memory T cells. In non-lymphoid organs CCR7 ligands are...

In this review, we take an in-depth look at the structural–functional domains of CCR7 and CCR7-bearing dendritic cell trajectory to lymph nodes. Then, we summarize the regulatory network of CCR7, including transcriptional regulation, translational and posttranslational regulation, internalization, desensitization, and recycling.

2021年8月3日 · In this review, we discuss the role of dendritic cells (DCs) and the central chemokine receptor CCR7 in the initiation and sustainment of selected chronic inflammatory diseases: multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis.

2023年9月1日 · Upon exposure to the CCR7 ligand CCL19, dendritic cells (DCs) effectively internalize the receptor and ligand as part of the canonical GPCR desensitization response. We show that CCR7 internalization also acts as an effective sink for the chemoattractant, dynamically shaping the spatiotemporal distribution of the chemokine.

cc趋化因子受体7（ccr7）在成熟的树突状细胞（dc）上选择性表达。ccr7配体，cc趋化因子配体（ccl）19和ccl21促进成熟dc从周围组织迁移到区域淋巴结。我们以前证明了ccr7配体在成熟dc中诱导了葡聚糖的快速受体介导的内吞作用。

Furthermore, CCR7 is the primary chemokine receptor that drives DC migration to the LN and, in turn, activates pathogenic T cells. Thus, antagonizing CCR7 at the ocular surface has been considered as a therapeutic strategy in corneal and ocular surface inflammatory disease.